Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
February 23, 2009
- NDAs Pending or Expected Soon for 3 Blockbuster Candidates: Novartis
February 16, 2009
- Chugai to Apply for 5 Products in 2009
February 16, 2009
- Takeda Starts PI in Japan for DPP-4 Inhibitor + Actos Combination
February 16, 2009
- Eli Lilly Japan to Conduct More PI Clinical Trials in Japan
February 16, 2009
- Astellas Has Strongest Image: NPhA Survey
February 16, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 16, 2009
- Council Recommends Health Insurance Coverage for KRAS Gene Mutation Tests
February 16, 2009
- MEDICAL DEVICE NEWS IN BRIEF
February 16, 2009
- PMDA to Take More PE-Based Post-Marketing Safety Measures
February 16, 2009
- Draft Guidance for Biosimilars Explained
February 16, 2009
- Strattera Recommended for Approval for AD/HD
February 16, 2009
- Astellas Withdraws NDA for Controlled-Release Formulation of Tacrolimus in US
February 16, 2009
- FDA Advisory Committee Recommends Approval of Prasugrel
February 16, 2009
- Ministerial Ordinance Issued Prohibiting Online Sale of Class 1, 2 OTC Drugs
February 16, 2009
- Takeda Obtains Approval for Lansoprazole's Successor in US
February 16, 2009
- Low Recognition Rate for AMD: Novartis Survey
February 16, 2009
- New GL Recommends Hp Eradication for All Hp-Related Diseases
February 16, 2009
- Japan's Most Admired Pharma Companies in 2008 P. Reed Maurer
February 16, 2009
- BD Expands Portfolio for Uterocervical Cancer Cytodiagnosis System
February 16, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…